A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema

In brief

Part A of the study is conducted to select the THR-149 dose level. Part B of the study is conducted to assess the efficacy and safety of the selected dose level compared to aflibercept, up to Month 3. As from Month 3, in about half of the subjects, the effect of a single flip-over injection (aflibercept or THR-149) will be evaluated when administered 1 month after the 3 monthly injections of THR-149 or aflibercept. In the other subjects, the durability of 3 monthly injections of THR 149 or aflibercept will be evaluated.

Key facts

Study ID
NCT04527107
Run by
Oxurion
People needed
135
Starts
2020-07-31
Expected to finish
2023-11-22
Last updated by the study team
2023-11-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.